CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
N-acetyl cysteine +1 moredrug
Likely dose
N-acetyl cysteine 5400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04005053
NCT04005053Phase 2Completed
CompareCT.gov

Identifying Biological Signatures of N-Acetylcysteine for Non-Suicidal Self-Injury in Adolescents and Young Adults

University of Minnesota·interventional·Posted Jul 2, 2019·Updated Aug 15, 2023

In Brief

A Phase 2 clinical trial evaluating N-acetyl cysteine and Placebo oral tablet for Self-Harm and 2 related conditions. Completed, enrolled 44 participants across 1 site.

Detailed Summary

To measure NAC-induced changes to concentrations of glutathione (GSH) in the anterior cingulate cortex (ACC) as measured by magnetic resonance spectroscopy (MRS) in 36 adolescents and young adults with NSSI (12 in each group: high, low, and placebo).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSelf-Harm, Depression, Suicide
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 2, 2019
Enrollment StartAug 1, 2019
Primary CompletionMay 8, 2022
Study CompletionOct 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 7 years ago

Interventions

N-acetyl cysteinedrug

3600 or 5400 mg/day N-acetyl cysteine

Placebo oral tabletdrug

Placebo